Highest-materiality recent filing
Vaccinex voluntarily delists from Nasdaq; Form 25 filing expected March 17, 2025
Nasdaq trading suspended since December 18, 2024 following a hearing panel determination to delist.
Vaccinex receives Nasdaq delisting notice; trading suspended Dec 18, 2024
Nasdaq Hearings Panel determined to delist VCNX for failing to maintain $2.5M minimum stockholders' equity.
Vaccinex raises $2.15M in private placement of stock and pre-funded warrants
Issued 76,909 shares at $3.25/share and pre-funded warrants for 584,646 shares at $3.2499 each.
Vaccinex receives Nasdaq delisting notice for failing equity standard; will appeal
Company failed to meet Nasdaq's minimum $2.5M stockholders' equity requirement for continued listing.
Vaccinex raises ~$6.2M via warrant exercise & new warrant issuance; insiders participate
Holders exercised 1,067,492 existing warrants at $5.636/share; gross proceeds ~$6.2M.
Vaccinex calls warrants after positive Alzheimer's trial FDG-PET signal
Warrants from Oct/Nov 2023, Feb/Mar 2024 financings called for cancellation at $0.0001/share.
Vaccinex reports pepinemab slows cognitive decline in MCI due to AD; plans partnership
Pepinemab showed significant reduction in brain metabolic decline (FDG-PET) in medial temporal cortex (p=0.0297) vs placebo.
Vaccinex reports positive SIGNAL-AD Phase 1b/2 data for pepinemab in Alzheimer's
Primary safety endpoint met: pepinemab well-tolerated; no serious treatment-related adverse events.
Vaccinex completes last patient visit in SIGNAL-AD Phase 1b/2 Alzheimer's study
Last patient completed final visit in randomized, double-blind Phase 1b/2 SIGNAL-AD study of pepinemab for Alzheimer's disease.
Vaccinex receives Nasdaq notice for failing minimum equity requirement
Nasdaq notice on April 11, 2024: Vaccinex lacks $2.5M minimum stockholders' equity for continued listing.
Vaccinex raises ~$4.5M via multiple equity financings; issues Series A Preferred and warrants
Gross proceeds: ~$1.5M from RDO + PIPE (193K shares and warrants at $7.77/unit).
Vaccinex closes $1.5M registered direct offering of 193K shares and warrants at $7.77 combined
Closed registered direct offering of 193,000 shares and warrants for 193,000 shares at $7.77 per unit.
Vaccinex implements 1-for-14 reverse stock split to regain Nasdaq minimum bid price compliance
Split effective 5:00 p.m. ET Feb 19, 2024; shares trade split-adjusted from Feb 20.
Vaccinex raises ~$3.7M in private placement of common stock and warrants
Issues 3.84M shares and warrants for 3.84M shares at $0.725 per unit; also 1.27M pre-funded warrants at $0.7249.
On March 18, 2025, Bala S. Manian informed Vaccinex, Inc. (the “Company”) of his resignation as a director of the Company effective immediately.
On September 10, 2024, Chrystyna Bedrij Stecyk informed Vaccinex, Inc. (the “Company”) of her resignation as a director of the Company effective immediately.
On February 27, 2024, Scott E. Royer notified Vaccinex Inc. (the “Company”) of his decision to retire from his position as the Company’s Chief Financial Officer effective March 14, 2024.
effective upon Mr. Royer’s retirement on March 14, 2024, Jill Sanchez, age 52, will serve as the Company’s Interim Chief Financial Officer and as its Principal Financial Officer and Principal Accounting Officer.
Max materiality 0.90 · Median 0.60 · Most common event other_material